Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S15–33.

Article  Google Scholar 

Rojo-Martínez G, Valdés S, Soriguer F, Vendrell J, Urrutia I, Pérez V, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10(1):2765.

Article  PubMed  PubMed Central  Google Scholar 

WWD. With 1 in 7 adults living with diabetes, Spain has second highest diabetes prevalence in Europe. 2021.

Arnold SV, Khunti K, Tang F, Chen H, Nicolucci A, Gomes MB, et al. Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: insights from the DISCOVER prospective cohort study. Endocrinol Diabetes Metab. 2022;5(2): e00321.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):95.

Article  PubMed  PubMed Central  Google Scholar 

Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19(5):421–30.

PubMed  PubMed Central  Google Scholar 

Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun S, Hisland L, Grenet G, Gueyffier F, Cornu C, Jaafari N, et al. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials. Therapie. 2022;77(4):413–23.

Article  PubMed  Google Scholar 

Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016;9(5):504–12.

Article  PubMed  PubMed Central  Google Scholar 

Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416–26.

Article  CAS  PubMed  Google Scholar 

Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327–38.

Article  PubMed  PubMed Central  Google Scholar 

Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–91.

Article  CAS  PubMed  Google Scholar 

Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P. Obesity and diabetes-Not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7): e3042.

Article  PubMed  PubMed Central  Google Scholar 

Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. The Lancet. 2022;399(10322):394–405.

Article  CAS  Google Scholar 

Association AD. Standards of medical care in diabetes—2019 Abridged for primary care providers. Clin Diabetes. 2019;37(1):11–34.

Article  Google Scholar 

Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.

Article  CAS  PubMed  Google Scholar 

Mata-Cases M, Vlacho B, Real J, Puig-Treserra R, Bundó M, Franch-Nadal J, et al. Trends in the degree of control and treatment of cardiovascular risk factors in people with type 2 diabetes in a primary care setting in Catalonia during 2007–2018. Front Endocrinol (Lausanne). 2021;12: 810757.

Article  PubMed  Google Scholar 

Rise MB, Pellerud A, Rygg L, Steinsbekk A. Making and maintaining lifestyle changes after participating in group based type 2 diabetes self-management educations: a qualitative study. PLoS ONE. 2013;8(5): e64009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damci T, Liebl A, et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96(11):3337–53.

Article  CAS  PubMed  Google Scholar 

Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes. 2016;34(1):3–21.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.

Article  Google Scholar 

de Pablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, DeRivas-Otero B, García-Sanchez R, Viguera-Ester P. Calidad de vida y satisfacción con el tratamiento de sujetos con diabetes tipo 2: resultados en España del estudio PANORAMA. Endocrinología y Nutrición. 2014; p. 18–26.

Perez A, Mediavilla JJ, Miñambres I, González-Segura D. Control glucémico en pacientes con diabetes mellitus tipo 2 en España. Revista Clínica Española. 2014; p. 429–36.

Barquilla García A, Llisterri Caro JL, Prieto Díaz MA, Alonso Moreno FJ, García Matarín L, Galgo Nafría A, et al. Control de la presión arterial en una población hipertensa diabética asistida en atención primaria: Estudio PRESCAP-Diabetes 2010. SEMERGEN - Medicina de Familia. 2015;41(1):13–23.

Article  PubMed  Google Scholar 

Díaz Vera AS, Abellán Alemán J, Segura Fragoso A, Martínez de Esteban JP, Lameiro Couso FJ, Golac Rabanal MDS, et al. The prevalence and risk factors associated with dyslipidemia in type 2 diabetic patients in the autonomous Region of Cantabria. Endocrinol Diabetes Nutr (Engl Ed). 2020;67(2):102–12.

PubMed  Google Scholar 

Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J. Características clínicas y económicas asociadas a la diabetes tipo 2. Revista Clínica Española. 2014; p. 121–30.

Mata-Cases M, Casajuana M, Franch-Nadal J, Casellas A, Castell C, Vinagre I, et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia. Spain Eur J Health Econ. 2016;17(8):1001–10.

Article  PubMed  Google Scholar 

Díaz-Cerezo S, Romera I, Sicras-Mainar A, López-Simarro F, Dilla T, Artime E, et al. Resource use and costs in patients with poorly controlled type 2 diabetes mellitus and obesity in routine clinical practice in Spain. Curr Med Res Opin. 2020;36(9):1449–56.

Article  PubMed  Google Scholar 

Orozco-Beltrán D, Cinza-Sanjurjo S, Escribano-Serrano J, López-Simarro F, Fernández G, Gómez García A, et al. Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting. Endocrinol Diabetes Metab. 2022;5(2): e00320.

Article  PubMed  Google Scholar 

Alonso-Morán E, Orueta JF, Nuño-Solinís R. Incidence of severe hypoglycaemic episodes in patients with type 2 diabetes in the Basque country: impact on healthcare costs. BMC Health Serv Res. 2015;15:207.

Article  PubMed  PubMed Central  Google Scholar 

Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.

Article  PubMed  Google Scholar 

Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–98.

Article  Google Scholar 

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.

Article  CAS  PubMed  Google Scholar 

Eeg-Olofsson K, Zethelius B, Gudbjornsdottir S, Eliasson B, Svensson AM, Cederholm J. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register. Diab Vasc Dis Res. 2016;13(4):268–77.

Article  CAS  PubMed  Google Scholar 

Perone F, Pingitore A, Conte E, Halasz G, Ambrosetti M, Peruzzi M, et al. Obesity and cardiovascular risk: systematic intervention is the key for prevention. Healthcare. 2023;11(6):902.

Article  PubMed  PubMed Central  Google Scholar 

Chobot A, Gorowska-Kowolik K, Sokolowska M, Jarosz-Chobot P. Obesity and diabetes-Not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7): e3042.

Article  PubMed  PubMed Central  Google Scholar 

Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187–94.

Article  PubMed  PubMed Central  Google Scholar 

Lindvig A, Tran MP, Kidd R, Tikkanen CK, Gæde P. The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark. Curr Med Res Opin. 2021;37(6):949–56.

Article  CAS  PubMed  Google Scholar 

Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. Adv Ther. 2020;37(2):869–82.

Article  PubMed  PubMed Central  Google Scholar 

Hellgren M, Svensson A-M, Franzén S, Ericsson Å, Gudbjörnsdottir S, Ekström N, et al. The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: a health economic modelling analysis based on nationwide data. Diabetes Obes Metab. 2021;23(7):1604–13.

Article  CAS